Deep Cleaning Device as a Treatment Is Effective for Blepharitis and Significantly Reduces Bacterial Load

To evaluate the efficacy and safety of the Deep Cleaning Device for the treatment of blepharitis.

This prospective, randomized controlled trial enrolled 51 adult patients with blepharitis, who were randomly allocated to two treatment groups. Group A (n = 26) received a combined therapy of sodium hyaluronate eye drops plus weekly device-assisted eyelid margin cleaning, while Group B (n = 25) received sodium hyaluronate eye drops as monotherapy. The primary efficacy indices included subjective symptoms, bacterial load of eyelid margin, and eyelid margin scale and hyperemia grading. Secondary efficacy indices covered meibomian gland expressibility, meibum quality, tear film stability, corneal fluorescein staining score, tear meniscus height, and lipid layer thickness. Safety indicators include best-corrected visual acuity, noninvasive intraocular pressure, and adverse events.

Group A exhibited significant improvements in reducing bacterial load and alleviating subjective symptoms compared to Group B. Objective signs, including eyelid margin scale grading and meibum quality score, also showed marked improvement. Safety assessments confirmed no significant changes in best-corrected visual acuity or intraocular pressure. No patient reported serious adverse reactions.

The Deep Cleaning Device is a safe and effective treatment for blepharitis, significantly reducing bacterial load and alleviating clinical symptoms. It represents a valuable addition to conventional therapies. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2200057855.